Navigation Links
Novel Test Identifies Leukemia Patients Likely to Respond to New Therapy

Researchers at the Albert Einstein College of Medicine of Yeshiva University have discovered a genetic signature identifying cases// of lymphoma that are uniquely susceptible to a newly developed molecular targeted therapy. As a result, physicians organizing clinical trials of the new therapy will be able to enroll patients who’ll be most likely to benefit from it.

The research was led by Dr. Ari Melnick, assistant professor of developmental & molecular biology and medicine at Einstein, who also developed the new lymphoma therapy. The study appears in the February 20 issue of the Proceedings of the National Academy of Sciences.

Each year more than 60,000 Americans are diagnosed with B cell lymphomas—tumors of cells of the immune system that include Hodgkin’s and non-Hodgkin’s lymphomas. B cells are the immune-system cells that make antibodies. Genetic aberrations can cause B cells to multiply uncontrollably, causing B cell lymphomas.

Dr. Melnick’s study focused on a gene called BCL6. The protein it codes for is a transcriptional repressor, which means that it can shut off the functioning of genes in B cells and other cells of the immune system and prevent them from being expressed. The BCL6 protein is normally produced only during a specific stage of B cell development and is never made again. But deregulation of BCL6 can cause the protein to be produced when it shouldn’t be. The unwelcome presence of the BCL6 protein blocks the expression of important genes that normally protect cells from becoming cancerous. As a result, malignant B-cell lymphomas occur.

Mutations or chromosomal rearrangements that deregulate BCL6 are responsible for many cases of diffuse large B cell lymphoma—an aggressive cancer that accounts for up to 30 percent of newly diagnosed non-Hodgkin’s lymphoma cases. In a 2004 Nature Medicine article, Dr. Melnick and colleagues described a peptide, which they dubbed BPI, that showed promise in treating B-cell lymphomas by specifically blocking the cancer-causing effects of the BCL6 protein. But until now, there has been no way to distinguish between diffuse large B cell lymphomas that are caused by BCL6 deregulation and those cases in which BCL6 is expressed but doesn’t actually drive the cancer.

Dr. Melnick reasoned that those diffuse large B cell lymphomas that are caused by BCL6 deregulation should have a characteristic 'signature' in which the genes targeted by the BCL6 protein are either expressed (turned on) or not expressed. The researchers used state-of-the-art genomics technology to analyze a panel of diffuse large B cell lymphoma cell lines. They found a set of 485 BCL6-controlled genes and confirmed that all lymphomas with the BCL6 signature are killed by BPI while lymphomas without the signature are resistant to the therapy.

'Suitable lymphoma patients—those whose tumor cells exhibit this BCL6 signature --will now have access to a potent and specific therapy that is unlikely to cause the side effects associated with chemotherapy drugs,' says Dr. Melnick. 'At the same time, lymphoma patients who don’t fit this genetic profile will be spared a drug treatment that would be ineffective for them.'

Source-Bio-Bio Technolgy
SRM
'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... ... January 19, 2017 , ... In 2009, Carol Bryan ... resulted in severe facial disfiguration. After four frightening years of isolation and emotional ... Medical Center, who removed the substances in a partial facial transplant through eight ...
(Date:1/19/2017)... ... January 19, 2017 , ... Workrite Ergonomics announced this ... The Tranquility privacy panel system was designed to deliver the ideal blend of ... noise and provide the visual privacy required to maintain concentration levels and increase ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... Sam ... planning assistance to commercial and residential clients in the California Bay Area, is launching ... heart health in the region. , Heart disease is the primary killer of adult ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... which serves Lawrenceville, New Jersey and the surrounding area, is inaugurating a ... sclerosis (ALS), more commonly known as Lou Gehrig's disease or motor neurone disease, ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Spring Create Real Impact contest from Impact Teen Drivers and California Casualty. Entries ... . , Educational grants totaling $15,000 will be awarded for the best ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... , January 19, 2017 According to a ... cryotherapy is set to witness a CAGR of 6.5% during the ... will continue to be the leading market for cryotherapy ... ... are emphasizing on ensuring affordable and adequate supply of gas in ...
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... blood analysis instruments and consumables for the medical and ... discuss its financial results for the third quarter fiscal ... be at 4:15 p.m. ET on Thursday, January 26, ... third quarter fiscal year 2017 after the market closes ...
Breaking Medicine Technology: